Effectiveness of the use of Omeprazolum (Oside) was studied in 24 patients with ulcer disease, 16 patients with chronic primary gastroduodenitis and 18 patients with acid reflux-esophagitis. The preparation Oside is a highly effective agent for the treatment of the aforementioned conditions and possesses a powerful antisecretory and antioxidant activity. Against the background of the use of the preparation the count of Helicobacter pylori gets decreased in the antral part of the stomach. The use of the preparation is not accompanied by side-effects and it does not have reverse acidic effect, in which respect has been shown to be superior to H2-histamine blockers.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of warning information at medication initiation on deprescribing intentions in older adults: A hypothetical vignette.
Patient Educ Couns
January 2025
University of Sydney School of Public Health Menzies Centre for Health Policy & Economics, Charles Perkins Centre (D17), The University of Sydney, NSW 2006, Australia; University of Bern Institute of Primary Health Care (BIHAM), Mittelstrasse 43, Bern 3012, Switzerland.
Objectives: To explore to what degree providing patients warning information about the long-term risks of a medication would affect their subsequent desire to discontinue it.
Methods: We conducted a vignette-based online experiment in which participants aged ≥ 65 years from the United States were asked to imagine starting and subsequently stopping omeprazole. Participants were randomized to one of four vignettes about starting omeprazole (potential long-term harms or no harm information; OTC vs.
Delineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.
Curr Drug Discov Technol
December 2024
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, 603203, India.
Background: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel.
View Article and Find Full Text PDFVonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease.
J Voice
January 2025
Department of Otolaryngology, Head and Neck Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; The First College of Clinical Medicine, Xuzhou Medical University, Xuzhou, China. Electronic address:
Objective: The aim is to examine the Reflux Symptom Score-12 (RSS-12) and assess the effectiveness of vonoprazan fumarate in managing laryngopharyngeal reflux disease (LPRD) among the Chinese population.
Methods: A total of 140 patients with LPRD who were treated at our otorhinolaryngology outpatient clinic were included. The patients were randomly divided into the vonoprazan treatment group and the esomeprazole treatment group.
The effect of the use of omeprazole versus famotidine on the kidney transplant function: a randomized controlled study.
Sci Rep
January 2025
Department of General and Transplant Surgery, Poznan University of Medical Sciences, 61-701, Poznan, Poland.
Tacrolimus is metabolized in the liver with the participation of cytochrome P450 isoforms 3A4 and 3A5 (CYP3A4, CYP3A5). Omeprazole, unlike famotidine, is a substrate and inhibitor of CYP2C19, CYP3A4, CYP3A5 enzymes. The aim of the study is to compare the effect of omeprazole and famotidine on the tacrolimus concentration and the kidney transplant function.
View Article and Find Full Text PDFA Pharmacokinetic/Pharmacodynamic Study of Esomeprazole Comparing a Dual Delayed-Release Formulation (YYD601) to a Conventional Formulation Following Multiple Administrations in Healthy Adult Subjects.
Drug Des Devel Ther
January 2025
School of Medicine, Kyungpook National University and Department of Clinical Pharmacology and Therapeutics, Kyungpook National University Hospital, Daegu, 41944, Republic of Korea.
Background: YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.
Purpose: This study aimed to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of YYD601 20 mg following single and multiple oral administrations in healthy, fasting adult Koreans, and to compare these outcomes to those of the conventional esomeprazole 20 mg capsule.
Methods: A randomized, open-label, two-period crossover study was conducted in 28 participants, who were divided into two treatment groups: one group received YYD601 20 mg, and the other received conventional esomeprazole 20 mg, once daily for five consecutive days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!